Clinical evaluation of tau-imaging PET tracer [18F]THK-5351

Clinical evaluation of tau-imaging PET tracer [18F]THK-5351 - Clinical evaluation of PET tracer [18F]THK-5351

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013929

Enrollment

Registered

2014-05-19

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

[18F]THK-5351 and [11C]PiB PET studies will be performed in the patients with Alzheimer&#39

s disease and healthy volunteers. Both PET scans will be performed within 3 months interval. Dynamic PET images of the brain will be acquired for 90 min after intravenous administration of 185 mBq [1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy normal subjects without cognitive impairment and cerebrovascular lesion, and probable Alzheimer's disease patients (NINCDS-ADRDA criteria)

Exclusion criteria

Exclusion criteria: Subjects with neuropsychiatric diseases other than Alzheimer's disease, subjects with severe cardiac abnormalities, and subjects with pacemaker or metal device in the body.

Design outcomes

Primary

Measure	Time frame
Regional [18F]THK-5351 and [11C]PiB retention in the brain, referenced to cerebellar cortex.	—

Countries

Japan

Contacts

Public ContactNobuyuki Okamura

Tohoku University School of Medicine Department of Pharmacology

nookamura@med.tohoku.ac.jp022-717-8058

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026